Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Mar;39(3):650–655. doi: 10.1128/AAC.39.3.650

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

D P Nicolau 1, C D Freeman 1, P P Belliveau 1, C H Nightingale 1, J W Ross 1, R Quintiliani 1
PMCID: PMC162599  PMID: 7793867

Abstract

Once-daily aminoglycoside (ODA) regimens have been instituted to maximize bacterial killing by optimizing the peak concentration/MIC ratio and to reduce the potential for toxicity. We initiated an ODA program at our institution that utilizes a fixed 7-mg/kg intravenous dose with a drug administration interval based on estimated creatinine clearance: > or = 60 ml/min every 24 h (q24h), 59 to 40 ml/min q36h, and 39 to 20 ml/min q48h. Subsequent interval adjustments are made by using a single concentration in serum and a nomogram designed for monitoring of ODA therapy. Since initiation of the program, 2,184 patients have received this ODA regimen. The median dose was 450 (range, 200 to 925) mg, while the median length of therapy was 3 (range, 1 to 26) days. The median age of the population was 46 (range, 13 to 97) years. Gentamicin accounted for 94% of the aminoglycoside use, and the majority (77%) of patients received the drug q24h. The 36-, 48-, and > 48-h intervals were used for 15, 6, and 2% of this population, respectively. Three patients exhibited clinically apparent ototoxicity. Twenty-seven patients (1.2%) developed nephrotoxicity (the Hartford Hospital historical rate is approximately 3 to 5%) after a median of 7 (range, 3 to 19) days of therapy. On the basis of a prospective evaluation of 58 patients and follow-up of additional patients via clinician reports, we have noted no apparent alterations in clinical response with our ODA program. This ODA program appears to be clinically effective, reduces the incidence of nephrotoxicity, and provides a cost-effective method for administration of aminoglycosides by reducing ancillary service time and serum aminoglycoside determinations.

Full Text

The Full Text of this article is available as a PDF (196.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beaucaire G., Leroy O., Beuscart C., Karp P., Chidiac C., Caillaux M. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother. 1991 May;27 (Suppl 100):91–103. doi: 10.1093/jac/27.suppl_c.91. [DOI] [PubMed] [Google Scholar]
  2. Begg E. J., Peddie B. A., Chambers S. T., Boswell D. R. Comparison of gentamicin dosing regimens using an in-vitro model. J Antimicrob Chemother. 1992 Apr;29(4):427–433. doi: 10.1093/jac/29.4.427. [DOI] [PubMed] [Google Scholar]
  3. Bennett W. M., Plamp C. E., Gilbert D. N., Parker R. A., Porter G. A. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis. 1979 Oct;140(4):576–580. doi: 10.1093/infdis/140.4.576. [DOI] [PubMed] [Google Scholar]
  4. Blaser J., Stone B. B., Groner M. C., Zinner S. H. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987 Jul;31(7):1054–1060. doi: 10.1128/aac.31.7.1054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  6. Craig W. A., Ebert S. C. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl. 1990;74:63–70. [PubMed] [Google Scholar]
  7. Davis B. D. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev. 1987 Sep;51(3):341–350. doi: 10.1128/mr.51.3.341-350.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ebert S. C., Craig W. A. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol. 1990 Jun;11(6):319–326. doi: 10.1086/646178. [DOI] [PubMed] [Google Scholar]
  9. Edson R. S., Terrell C. L. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, netilmicin, and sisomicin. Mayo Clin Proc. 1987 Oct;62(10):916–920. doi: 10.1016/s0025-6196(12)65048-4. [DOI] [PubMed] [Google Scholar]
  10. Franson T. R., Quebbeman E. J., Whipple J., Thomson R., Bubrick J., Rosenberger S. L., Ausman R. K. Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods. Crit Care Med. 1988 Sep;16(9):840–843. doi: 10.1097/00003246-198809000-00004. [DOI] [PubMed] [Google Scholar]
  11. Gilbert D. N. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991 Mar;35(3):399–405. doi: 10.1128/aac.35.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Keating M. J., Bodey G. P., Valdivieso M., Rodriguez V. A randomized comparative trial of three aminoglycosides--comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine (Baltimore) 1979 Mar;58(2):159–170. doi: 10.1097/00005792-197903000-00004. [DOI] [PubMed] [Google Scholar]
  13. Levy R. H., Bauer L. A. Basic pharmacokinetics. Ther Drug Monit. 1986;8(1):47–58. doi: 10.1097/00007691-198603000-00010. [DOI] [PubMed] [Google Scholar]
  14. McCormack J. P., Jewesson P. J. A critical reevaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis. 1992 Jan;14(1):320–339. doi: 10.1093/clinids/14.1.320. [DOI] [PubMed] [Google Scholar]
  15. Moore R. D., Lietman P. S., Smith C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 Jan;155(1):93–99. doi: 10.1093/infdis/155.1.93. [DOI] [PubMed] [Google Scholar]
  16. Nordström L., Ringberg H., Cronberg S., Tjernström O., Walder M. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother. 1990 Jan;25(1):159–173. doi: 10.1093/jac/25.1.159. [DOI] [PubMed] [Google Scholar]
  17. Perkins M. W. Failure of a nomogram to achieve target aminoglycoside concentrations. Br J Clin Pharmacol. 1990 Apr;29(4):495–496. doi: 10.1111/j.1365-2125.1990.tb03670.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Prins J. M., Büller H. R., Kuijper E. J., Tange R. A., Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993 Feb 6;341(8841):335–339. doi: 10.1016/0140-6736(93)90137-6. [DOI] [PubMed] [Google Scholar]
  19. Reed R. L., 2nd, Wu A. H., Miller-Crotchett P., Crotchett J., Fischer R. P. Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients. J Trauma. 1989 Nov;29(11):1462–1470. doi: 10.1097/00005373-198911000-00002. [DOI] [PubMed] [Google Scholar]
  20. Sawchuk R. J., Zaske D. E. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976 Apr;4(2):183–195. doi: 10.1007/BF01086153. [DOI] [PubMed] [Google Scholar]
  21. Sturm A. W. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis. 1989 May;159(5):931–937. doi: 10.1093/infdis/159.5.931. [DOI] [PubMed] [Google Scholar]
  22. Zarowitz B. J., Robert S., Peterson E. L. Prediction of glomerular filtration rate using aminoglycoside clearance in critically ill medical patients. Ann Pharmacother. 1992 Oct;26(10):1205–1210. doi: 10.1177/106002809202601001. [DOI] [PubMed] [Google Scholar]
  23. Zaske D. E., Cipolle R. J., Strate R. J. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery. 1980 Feb;87(2):164–169. [PubMed] [Google Scholar]
  24. Zhanel G. G., Hoban D. J., Harding G. K. The postantibiotic effect: a review of in vitro and in vivo data. DICP. 1991 Feb;25(2):153–163. doi: 10.1177/106002809102500210. [DOI] [PubMed] [Google Scholar]
  25. de Vries P. J., Verkooyen R. P., Leguit P., Verbrugh H. A. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis. 1990 Mar;9(3):161–168. doi: 10.1007/BF01963832. [DOI] [PubMed] [Google Scholar]
  26. ter Braak E. W., de Vries P. J., Bouter K. P., van der Vegt S. G., Dorrestein G. C., Nortier J. W., van Dijk A., Verkooyen R. P., Verbrugh H. A. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990 Jul;89(1):58–66. doi: 10.1016/0002-9343(90)90099-y. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES